Wang Peng-Fei, Song Si-Ying, Wang Ting-Jian, Ji Wen-Jun, Li Shou-Wei, Liu Ning, Yan Chang-Xiang
Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
School of Basic Medical Sciences, Capital Medical University, Beijing, China.
Oncoimmunology. 2018 Jul 30;7(10):e1494113. doi: 10.1080/2162402X.2018.1494113. eCollection 2018.
Myeloid-derived suppressor cells (MDSCs) have been shown to contribute to tumor progression, mainly through immune suppression. Inverse correlations have been observed between MDSC levels and patient survival for various malignancies. The purpose of this meta-analysis was to evaluate the prognostic value of pretreatment circulating MDSCs. We searched MEDLINE and EMBASE from their inceptions to September 2017 to identify relevant articles. Using a fixed or random effects model, pooled hazard ratios (HRs) were estimated for overall survival (OS) and combined disease-free survival, progression-free survival, and recurrence-free survival (DFS/PFS/RFS). A total of 40 studies comprising 2721 were included. For solid tumors, high levels of pretreatment circulating MDSCs were significantly associated with worse OS (HR = 1.796, 95% CI = 1.587-2.032) and DFS/PFS/RFS (HR = 2.459, 95% CI = 2.018-2.997). Breast cancer showed the largest association between high MDSC levels and worse OS (pooled HR = 3.053). Elevated MDSCs were also associated with worse OS for mixed-stage tumors (pooled HR = 1.659) and advanced-stage tumors (pooled HR = 2.337). Furthermore, both monocytic-MDSCs (M-MDSCs) and granulocytic or polymorphonuclear (PMN-MDSCs) showed negative associations with survival outcomes. Overall, high levels of pretreatment circulating MDSCs negatively influenced survival in most cancers. Pretreatment circulating MDSCs should be taken into account to further improve prognostic evaluation and develop novel therapeutic strategies.
髓源性抑制细胞（MDSCs）已被证明主要通过免疫抑制作用促进肿瘤进展。在各种恶性肿瘤中，已观察到MDSC水平与患者生存率呈负相关。本荟萃分析的目的是评估治疗前循环MDSCs的预后价值。我们检索了MEDLINE和EMBASE自创建至2017年9月的文献，以识别相关文章。使用固定或随机效应模型，估计总生存期（OS）以及综合无病生存期、无进展生存期和无复发生存期（DFS/PFS/RFS）的合并风险比（HRs）。共纳入40项研究，涉及2721例患者。对于实体瘤，治疗前循环MDSCs水平较高与较差的OS（HR = 1.796，95%CI = 1.587 - 2.032）以及DFS/PFS/RFS（HR = 2.459，95%CI = 2.018 - 2.997）显著相关。乳腺癌中，MDSC水平较高与较差的OS之间的关联最为显著（合并HR = 3.053）。MDSCs升高还与混合期肿瘤（合并HR = 1.659）和晚期肿瘤（合并HR = 2.337）较差的OS相关。此外，单核细胞型MDSCs（M-MDSCs）和粒细胞或多形核细胞型MDSCs（PMN-MDSCs）均与生存结局呈负相关。总体而言，治疗前循环MDSCs水平较高对大多数癌症的生存有负面影响。应考虑治疗前循环MDSCs水平，以进一步改善预后评估并制定新的治疗策略。
